{
  "run_id": "RUN_20260205_073751_f71574fffb78",
  "timestamp": "2026-02-05T09:40:27.149212",
  "document": "Very-Long-Chain-Acyl-CoA-Dehydrogenase-Deficiency-(LCAD).pdf",
  "document_path": "/Users/frederictetard/Projects/ese/gold_data/NLP4RARE/dev/Very-Long-Chain-Acyl-CoA-Dehydrogenase-Deficiency-(LCAD).pdf",
  "pipeline_version": "0.8",
  "total_candidates": 2,
  "total_validated": 2,
  "total_rejected": 0,
  "total_investigational": 0,
  "drugs": [
    {
      "matched_text": "long-chain acyl-CoA dehydrogenase",
      "preferred_name": "Long-chain acyl-CoA dehydrogenase",
      "brand_name": null,
      "compound_id": null,
      "confidence": 0.7,
      "is_investigational": false,
      "drug_class": null,
      "mechanism": null,
      "development_phase": null,
      "sponsor": null,
      "conditions": [],
      "nct_id": null,
      "dosage_form": null,
      "route": null,
      "marketing_status": null,
      "codes": {
        "rxcui": null,
        "mesh": null,
        "ndc": null,
        "drugbank": null,
        "unii": null
      },
      "all_identifiers": [
        {
          "system": "RxCUI",
          "code": "28880",
          "display": null
        }
      ],
      "context": "Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD) is a rare genetic disorder of fatty acid metabolism that is transmitted as an autosomal recessive trait. It occurs when an enzyme",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_lexicon_drug.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "tandem",
      "preferred_name": "Tandem",
      "brand_name": null,
      "compound_id": null,
      "confidence": 0.7,
      "is_investigational": false,
      "drug_class": null,
      "mechanism": null,
      "development_phase": null,
      "sponsor": null,
      "conditions": [],
      "nct_id": null,
      "dosage_form": null,
      "route": null,
      "marketing_status": null,
      "codes": {
        "rxcui": null,
        "mesh": "C017738",
        "ndc": null,
        "drugbank": null,
        "unii": null
      },
      "all_identifiers": [
        {
          "system": "RxCUI",
          "code": "37565",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "C017738",
          "display": "TANDEM (quinoxaline)"
        }
      ],
      "context": "ually VLCADD. VLCADD was originally described in 1992 and is now recognized as having an incidence of 1:40,000 babies. The introduction of heel-stick tandem mass spectrometry for the early diagnosis of VLCAD in newborns has markedly increased the number of infants in which the disorder is detected.",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_lexicon_drug.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "TANDEM (quinoxaline)",
      "enrichment_source": "pubtator3"
    }
  ]
}